Navigation Links
Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Date:7/16/2008

) R (p<0.001). Type 2 patients (n=173) receiving VIAject(TM) showed a weight reduction (-0.5 +/- 4.7 kg) compared to baseline, while a weight gain (0.8 +/- 6.2 kg) was seen in the patients (n=180) receiving Humulin(R) R (p<0.05), for a net difference of 1.3 kg.

The interim results demonstrated statistically significant daily meal-time (prandial) dose reductions in patients with Type 1 and Type 2 diabetes using VIAject(TM) compared to Humulin(R) R in the first six weeks of the study. With comparable glycemic control targets between treatment groups, Type 1 patients (n=106) receiving VIAject(TM) showed a 34 percent reduction in daily prandial dose (10 units; p<0.001) compared to baseline, while control patients receiving Humulin(R) R showed a non-significant 7 percent reduction (2.4 units). Type 2 patients receiving VIAject(TM) showed a 36 percent reduction (16 units; p<0.001), while control patients receiving Humulin(R) R showed an increase of 15 percent (6 units; p<0.01), for a net difference of 51 percent.

The interim results demonstrated statistically significant reductions in mild and moderate hypoglycemic events in patients with Type 1 and Type 2 diabetes using VIAject(TM) compared to Humulin(R) R. Type 1 patients recorded 8,111 mild and moderate hypoglycemic events, with a significantly lower number of incidents in the VIAject(TM) group (3,691; p<0.001) than in the Humulin(R) R group (4,420). Type 2 patients recorded 2,438 mild and moderate hypoglycemic events with a significantly lower number of incidents in the VIAject(TM) group (844 events) than in the Humulin(R) R group (1,594 events; p<0.001).

Biodel noted that the final data from these trials may differ from those suggested by the preliminary interim analysis. Furthermore the primary efficacy endpoint for the studies, change in HbA1c, has not been analyzed. Both HbA1c and incidences of severe hypoglycemic events will be analyzed and reported after the clinical trial database for the s
'/>"/>

SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
4. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
5. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
6. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
7. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
8. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
9. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
10. Sosei Announces Completion of Phase III Trial for NorLevo(R)
11. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Nektar Therapeutics (Nasdaq: NKTR ) today reported its ... Cash and investments in marketable securities at ... million at March 31, 2014."The second half of 2014 will ... to significant milestones for a number of our late-stage clinical ... of Nektar. "The first of these is the potential US ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... offer health plans and employers effective options to ... narrow networks argue that they can enhance formulary ... administrative fees. Consultants report that nearly all PBMs ... to requests for proposals. The Aug. 12 ...
(Date:8/1/2014)... 2014 Millions of women suffer with ... and in some cases the arms, causing an abnormal ... 17 million women in the U.S. alone are affected. ... the pain, embarrassment and discomfort caused by lipedema, it’s ... are unaware that this is a disease,” says Dr. David ...
(Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... important developments about chemical listings, appellate decisions, litigation ... that may affect compliance with California's Proposition 65. ... to the law, regulations, history and trends impacting ... the fourth installment of the series which adds ...
(Date:7/31/2014)... recently used birth control pills containing high-dose estrogen and ... breast cancer, whereas women using some other formulations did ... , a journal of the American Association for Cancer ... oral contraceptives [birth control pills] in the past year ... to never or former oral contraceptive use, and that ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2
... is a sad day for the American labor movement and ... the bottom up, rather than the top down.SEIU,s press release ... It also is predictable that Hearing Officer Ray Marshall, former ... Stern to conduct the hearing would do the job he ...
... 22 Novo Nordisk, a global healthcare company focusing on ... "100 Best Companies to Work For" awards issue. This is ... award -- one of the most influential business scorecards in ... For" are historically good performers in the marketplace for not ...
... 22 Missouri Congressman Roy Blunt today reflected on the ... v. Wade by speaking with the Missouri-Illinois Right to Life ... in sending a letter to President Barack Obama urging him ... "The last few years are the first time since I,ve ...
... preventable blindnessOAK BROOK, Ill., Jan. 22 The ... http://www.newscom.com/cgi-bin/prnh/20081014/DC38855LOGO ) Who: Former President ... Lions Clubs International President Albert Brandel; ... Dedication of the "Gift of Sight" statue, ...
... 22 Griffin Hospital has been honored with a 10th year ... Griffin ranked 62 on the 2009 list released today. Griffin is ... ten years.Griffin was first invited to apply for selection to the ... since. FORTUNE has issued the list of "100 Best Companies to ...
... announced today that,the physicians of Midwest Pulmonary and ... , The physicians are Susan ... Plumb, M.D. All are board-certified in pulmonology,and critical care ... the treatment of sleep disorders. , ...
Cached Medicine News:Health News:Statement by UHW on SEIU's Claims Regarding SEIU-Trusteeship Hearing Process Chaired by Ray Marshall 2Health News:Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For' 2Health News:Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For' 3Health News:Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation 2Health News:Blunt Marks Anniversary of Roe v. Wade, Signs Letter in Defense of Pro-Life Legislation 3Health News:Former President Jimmy Carter Dedicates 'Gift of Sight' Statue at Lions Club International Headquarters in Recognition of Lions' Blindness Prevention Efforts 2Health News:Griffin Honored with Tenth Year on FORTUNE Best Companies to Work for List 2Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2
A sturdy, robust stool. Gas operated height adjustment for convenience....
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 27 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Medicine Products: